High-dose cyclophosphamide for autoimmunity and alloimmunity
- PMID: 20087683
- DOI: 10.1007/s12026-009-8149-y
High-dose cyclophosphamide for autoimmunity and alloimmunity
Abstract
High-dose cyclophosphamide (high-CY) is a potent immunosuppressive regimen that is increasingly used to mitigate both autoimmune and alloimmune conditions. Differential expression of aldehyde dehydrogenase between hematopoietic stem cells and lymphocytes accounts for the differential sensitivity of these cells to high-CY and explains why this regimen is immunosuppressive but not myeloablative. This article describes the clinical translation of high-CY for the treatment of autoimmune and alloimmune conditions.
Similar articles
-
High-dose cyclophosphamide for aplastic anemia and autoimmunity.Curr Opin Oncol. 2002 Mar;14(2):143-6. doi: 10.1097/00001622-200203000-00001. Curr Opin Oncol. 2002. PMID: 11880702 Review.
-
High dose cyclophosphamide treatment for autoimmune disorders.ScientificWorldJournal. 2002 Jun 28;2:1808-15. doi: 10.1100/tsw.2002.863. ScientificWorldJournal. 2002. PMID: 12806171 Free PMC article. Review.
-
A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome.Ann Hematol. 2012 Sep;91(9):1459-69. doi: 10.1007/s00277-012-1462-x. Epub 2012 Apr 18. Ann Hematol. 2012. PMID: 22526363 Clinical Trial.
-
Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study.Biol Blood Marrow Transplant. 2010 Nov;16(11):1582-8. doi: 10.1016/j.bbmt.2010.05.010. Epub 2010 May 26. Biol Blood Marrow Transplant. 2010. PMID: 20685256 Clinical Trial.
-
An immunoablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD.Biol Blood Marrow Transplant. 2000;6(2A):182-9. doi: 10.1016/s1083-8791(00)70041-3. Biol Blood Marrow Transplant. 2000. PMID: 10816026
Cited by
-
Low-dose oral cyclophosphamide therapy reduces atherosclerosis progression by decreasing inflammatory cells in a murine model of atherosclerosis.Int J Cardiol Heart Vasc. 2020 May 10;28:100529. doi: 10.1016/j.ijcha.2020.100529. eCollection 2020 Jun. Int J Cardiol Heart Vasc. 2020. PMID: 32577494 Free PMC article.
-
Effects of Shrimp Peptide Hydrolysate on Intestinal Microbiota Restoration and Immune Modulation in Cyclophosphamide-Treated Mice.Molecules. 2022 Mar 6;27(5):1720. doi: 10.3390/molecules27051720. Molecules. 2022. PMID: 35268821 Free PMC article.
-
Combination therapy: A feasibility strategy for CAR-T cell therapy in the treatment of solid tumors.Oncol Lett. 2018 Aug;16(2):2063-2070. doi: 10.3892/ol.2018.8946. Epub 2018 Jun 11. Oncol Lett. 2018. PMID: 30008901 Free PMC article. Review.
-
B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders.Pharmaceuticals (Basel). 2021 Jan 6;14(1):37. doi: 10.3390/ph14010037. Pharmaceuticals (Basel). 2021. PMID: 33419217 Free PMC article. Review.
-
Compatibility effects of ginseng and Ligustrum lucidum Ait herb pair on hematopoietic recovery in mice with cyclophosphamide-induced myelosuppression and its material basis.J Ginseng Res. 2020 Mar;44(2):291-299. doi: 10.1016/j.jgr.2019.01.001. Epub 2019 Jan 11. J Ginseng Res. 2020. PMID: 32148411 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical